Author:
Sánchez Montero Silvia,Monfa Guix Elena,Sierra Ausín Mónica,Izquierdo García Francisco,León Gómez Benjamín,Martínez-Rosero Caterine Vanesa,Martelli Guerrero Xhamy Yosue,Romero Zaldumbide Erika Jenelia,Prieto Velasco Mario Alfredo,Lucas Álvarez Cristina,Sastre López Aránzazu,Estifan Kasabji George
Reference5 articles.
1. Biologics and Targeted Synthetic Drugs Can Induce Immune-Mediated Glomerular Disorders in Patients with Rheumatic Diseases: An Updated Systematic Literature Review;Chessa;BioDrugs.,2021
2. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis;Stokes;Nephrol Dial Transplant.,2005
3. Crohn disease complicated by IgA vasculitis during therapy with tumor necrosis factor-α inhibitor;Hokama;Pol Arch Intern Med.,2019
4. IgA Nephropathy in the Setting of Anti-TNF-α Therapy for Inflammatory Bowel Disease;Strobel;ACG Case Rep J.,2020
5. International Society of Nephrology. Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guideline for glomerulonephritis. Chapter 2: Immunoglobulin A nephropathy (IgAN)/immunoglobulin A vasculitis (IgAV). Kidney Int 2021;100:S1-S276.